|  | Conditions & Treatments | Depression

Effective Depression Treatments: A Comprehensive Guide to Evidence-Based Options

Major depressive disorder (MDD) is a heterogeneous condition requiring individualized, often multimodal treatment. Guidelines (APA, NICE, CANMAT) recommend stepped care based on severity, chronicity, comorbidities, and patient preference.

1. Psychotherapy (First-Line for Mild-Moderate; Combined for Moderate-Severe)

  • Cognitive Behavioral Therapy (CBT): Identifies/modifies negative automatic thoughts, behavioral activation, relapse prevention. 12–20 sessions.
  • Interpersonal Therapy (IPT): Focuses on role transitions, grief, disputes, deficits. 12–16 sessions.
  • Behavioral Activation (BA): Simpler, effective; increases rewarding activities.
  • Problem-Solving Therapy (PST): Structured coping skill building.
  • Mindfulness-Based Cognitive Therapy (MBCT): Relapse prevention in recurrent MDD.
  • Psychodynamic, ACT, EMDR: Evidence for specific presentations.

2. Pharmacotherapy (First-Line for Moderate-Severe; Combined with Therapy)

Augmentation: atypical antipsychotics (aripiprazole, quetiapine XR, brexpiprazole), lithium, thyroid hormone, buspirone, ketamine/esketamine (TRD).

3. Neuromodulation

  • ECT: Gold standard for severe, psychotic, catatonic, high suicide risk. 70–90% response.
  • rTMS: FDA-cleared for TRD; non-invasive, outpatient.
  • VNS, DBS: Refractory cases; surgical.

4. Lifestyle & Complementary

  • Exercise: Aerobic 150 min/wk = moderate antidepressant effect.
  • Sleep hygiene: CBT-I for insomnia.
  • Diet: Mediterranean, anti-inflammatory; omega-3 (EPA > DHA) adjunctive.
  • Light therapy: 10,000 lux × 30 min AM for SAD/non-seasonal.
  • Supplements: S-adenosylmethionine (SAMe), folate (L-methylfolate), vitamin D (if deficient).

5. Treatment-Resistant Depression (TRD) Algorithm

  1. Optimize dose/duration (8–12 wks).
  2. Switch within/between classes.
  3. Augment.
  4. Combine psychotherapy.
  5. Consider neuromodulation (rTMS → ECT).
  6. Esketamine nasal spray + oral AD.

6. Special Populations

  • Perinatal: Sertraline preferred; risk-benefit discussion.
  • Geriatric: Start low, go slow; watch falls, hyponatremia, interactions.
  • Adolescent: Fluoxetine only FDA-approved; monitor suicidality.
  • Bipolar depression: Avoid antidepressant monotherapy; use mood stabilizer + atypical antipsychotic.

Monitoring & Follow-Up

PHQ-9 q2–4 wks initially. Remission = PHQ-9 <5. Continue acute phase treatment 6–12 months after remission to prevent relapse. Maintenance for recurrent (>3 episodes) or chronic (>2 years).

Depression - Related Articles

Health Sciences © https://www.222health.com

ClassExamplesKey Notes
SSRIsSertraline, escitalopram, fluoxetine, paroxetine, citalopramFirst-line; favorable safety; GI/sexual side effects; 4–8 wk onset
SNRIsVenlafaxine, duloxetine, desvenlafaxineDual NE/5-HT; pain comorbidities; discontinuation syndrome
AtypicalBupropion, mirtazapine, vortioxetine, vilazodoneBupropion: activating, no sexual SE; Mirtazapine: sedating, weight gain
Tricyclics (TCAs)Amitriptyline, nortriptyline, imipramineEffective but anticholinergic, cardiac toxicity in OD; 2nd/3rd line
MAOIsPhenelzine, tranylcypromine, selegiline (patch)Treatment-resistant; tyramine diet, drug interactions